Yahoo Finance
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
Pfizer and Starbucks both raised their outlooks this summer, but their recovery trajectories differ in sustainability and investor relevance.
3 stories · last 7 days by relevance
Pfizer and Starbucks both raised their outlooks this summer, but their recovery trajectories differ in sustainability and investor relevance.
Starbucks paid down $1.8 billion in debt, reducing leverage and financing costs while maintaining strong liquidity and borrowing capacity—signaling reinforced financial flexibility for capital allocat
Chagee Holdings released second-quarter 2026 financial results, continuing to report performance as a publicly traded premium tea drinks brand.